IMMUNOGENE THERAPY OF TUMORS WITH A VACCINE BASED ON THE LIGAND-BINDING DOMAIN OF CHICKEN HOMOLOGOUS INTEGRIN β₃

References

• Folkman J. What is the Evidence that Tumors are Angiogenesis Dependent?. J. Natl. Cancer Inst. 1990; 82(1)4–6
   PubMed Web of Science ®Google Scholar
• Ferrara N., Alitalo K. Clinical Application of Angiogeneic Growth Factors and their Inhibitors. Nat. Med. 1999; 5(12)1359–1364
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanism of Angiogenesis. Nature 1997; 386(6626)671–674
   PubMed Web of Science ®Google Scholar
• Zetter B.R. Angiogenesis and Tumor Metastasis. Annu. Rev. Med. 1998; 49(2)407–424
   Google Scholar
• Cao R., Wu H.-L., Vettonmaki N., Linden P., Farnebo J., Shi G.-Y., Cao Y. Suppression of Angiogenesis and Tumor Growth by the Inhibitor K1-5 Generated by Plasmin-Mediated Proteolysis. Proc. Natl. Acad. Sci. USA 1999; 96(10)5728–5733
   PubMed Web of Science ®Google Scholar
• O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S. Endostatin: an Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 1997; 88(2)277–285
   PubMed Web of Science ®Google Scholar
• Kerbel R.S. A Cancer Therapy Resistant to Resistant. Nature 1997; 390(6658)335–336
   Google Scholar
• Fidler I.J., Ellis L.M. The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis. Cell 1994; 79(1)185–188
   Google Scholar
• Arap W., Pasqualini R., Ruoslahti E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 1998; 279(5349)377–379
   PubMed Web of Science ®Google Scholar
• Eliceiri B.P., Cheresh D.A. The Role of Integrins during Angiogenesis: Insights into Potential Mechanisms of Action and Clinical Development. J. Clin. Invest. 1999; 103(9)1227–1230
   PubMed Web of Science ®Google Scholar
• Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., Cheresh D.A. Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an αvβ3 Antagonist. J. Clin. Invest. 1999; 103(1)47–54
   PubMed Web of Science ®Google Scholar
• Drake C.J., Cheresh D.A., Little C.D. An Antagonist of Integrin αvβ3 Prevents Maturation of Blood Vessels During Embryonic Neovascularization. J. Cell Sci. 1995; 108(7)2655–2661
   Google Scholar
• Xiong J.-P., Thilo S., Beate D., Zhang R.-G., Reinhardt D., David L.S., Andrzej J., Simon L.G., Amin A. Crystal Structure of the Extracellular Segment of Integrin αvβ3. Science 2001; 294(5541)339–345
   PubMed Web of Science ®Google Scholar
• Lode H.N., Moehler T., Jonczyk A., Giwies S.D., Cheresh D.A., Reisfeld R.A. Synergy between an Antiangiogeneic Integrin αv Antagonist and an Antibody-Cytokine Fusion Protein Eradicates Spontaneous Tumor Metastasis. Proc. Natl. Acad. Sci. USA 1999; 96(4)1591–1596
   PubMed Web of Science ®Google Scholar
• Schultz J.F., Armant D.R. β1- and β3-Class Integrins Mediate Fibronectin Binding Activity at the Surface of Developing Mouse Peri-Implantation Blastocysts. J. Biol. Chem. 1995; 270(19)11522–11531
   Google Scholar
• Lin E.C., Carron C.P., Meyer D.M., Smith J.W. A Series of Function Blocking Antibodies against the Alpha v Beta 3 Integrin Bind Allosteric to the Ligand-Binding Site and Induce Ligand Dissociation. Cell Adhes. Commun. 1998; 6(3)451–464
   Google Scholar
• Brooks P.C., Clark R.A.F., Cheresh D.A. Requirement of Vascular Integrin αvβ3 for Angiogenesis. Science 1994; 264(5158)569–571
   PubMed Web of Science ®Google Scholar
• Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., T.-H., Klier G., Cheresh D.A. Integrin αvβ3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels. Cell 1994; 79(7)1157–1164
   PubMed Web of Science ®Google Scholar
• Kornberg T.B., Krasnow M.A. The Drosophila Genome Sequence: Implications for Biology and Medicine. Science 2000; 287(5461)2218–2220
   Google Scholar
• Wei Y.-Q., Hang M.-J., Yang L., Zhao X., Tian L., Lu Y., Shu J.-M., Lu C.-J., Niu T., Kang B., Mao Y.-Q., Liu F., Wun Y.-J., Lei S., Lou F., Zhou L.-Q., Peng F., Jiang Y., Liu J.-Y., Zhou H., Wang Q.-R., He Q.-M., Xiao F., Lou Y.-Y., Li Q., Wu Y., Ding Z.-Y., Hu B., Hu M., Zhang W. Immunogene Therapy of Tumors with Vaccine based on Xenopus Homologous Vascular Endothelial Growth Factor as a Model Antigen. Proc. Natl. Acad. Sci. USA 2001; 98(20)11545–11550
   PubMed Web of Science ®Google Scholar
• Wei Y.-Q., Zhao X., Kariya Y., Fukata H., Teshigawara K., Uchida A. Induction of Apoptosis by Quercetin: Involvement of Heat Shock Protein. Cancer Res. 1994; 54(18)4952–4956
   PubMed Web of Science ®Google Scholar
• Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., Maliszewski C.R. Distinct Dendritic Cell Subsets Differentially Regulate the Class of Immune Response In Vivo. Proc. Natl. Acad. Sci. USA 1999; 96(3)1036–1041
   PubMed Web of Science ®Google Scholar
• Kumar C.C., Malkowski M., Yin Z.-Z., Tanghetti E., Yaremko B., Nechuta T., Varner J., Liu M., Smith E.M., Neustadt B., Presta M., Armstrong L. Inhibition of Angiogenesis and Tumor Growth by SCH221153, a dual αvβ3 and αvβ5 Integrin Receptor Antagonist. Cancer Res. 2001; 61(5)2232–2238
   Google Scholar
• Wei Y.-Q., Wang Q.-R., zhao X., Yang L., Tian L., Lu Y., Kang B., Lu C.-J., Hang M.-J., Lou Y.-Y., Xiao F., He Q.-M., Shu J.-M., Xie X.-J., Mao Y.-Q., Lei S., Lou F., Zhou L.-Q., Liu C.-E., Zhou H., Jiang Y., Peng F., Yuan L.-P., Li Q., Wu Y., Liu J.-Y. Immunotherapy of Tumors with Xenogeneic Endothelial Cells as a Vaccine. Nat. Med. 2000; 6(10)1160–1166
   PubMed Web of Science ®Google Scholar
• Horton H.M., Anderson D., Hernandez P., Barnhart K.M., Norman J.A. A Gene Therapy for Cancer using Intramuscular Injection of Plasmid DNA Encoding Interferon α. Proc. Natl. Acad. Sci. USA 1999; 96(4)1553–1558
   PubMed Web of Science ®Google Scholar
• Blezinger P., Wang J.-J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., Wang M. Systemic Inhibition of Tumor Growth and Tumor Metastases by Intramuscular Administration of the Endostatin gene. Nat. Biotechnol. 1999; 17(1)343–348
   Google Scholar
• Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma. N. Engl. J. Med 1991; 324(1)1–8
   PubMed Web of Science ®Google Scholar
• Boon T., Coulie P.G., Eynde B. Tumor Antigens Recognized by T Cells. Immunol. Today 1997; 18(6)267–268
   PubMedGoogle Scholar
• Rosenberg S.A. Cancer Vaccines based on the Identification of Genes Encoding Cancer Regression Antigens. Immunol. Today 1997; 18(4)175–178
   PubMedGoogle Scholar
• Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin αvβ3 Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin. J. Clin. Invest. 1995; 96(4)1815–1822
   PubMed Web of Science ®Google Scholar
• Kang I.-C., Lee Y.-D., Kim D.-S. A Novel Disintegrin Salmosin Inhibits Tumor Angiogenesis. Cancer Res. 1999; 59(15)3754–3760
   PubMed Web of Science ®Google Scholar
• Hynes R.O. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell 1992; 69(1)11–25
   PubMed Web of Science ®Google Scholar
• Kieffer N., Phillips D.R. Platelet Membrane Glycoproteins: Functions In Cellular Interactions. Annu. Rev. Cell Biol. 1990; 6(2)329–357
   Google Scholar
• Du X.P., Plow E.F., Frelinger A.L. III, O'Toole T.E., Loftus J.C., Ginsberg M.H. Ligands “Activate” Integrin alphaIIbbeta3 (platlet GPIIb-IIIa). Cell 1991; 65(6)961–971
   Google Scholar
• Frelinger A.L. III, Du X.P., Plow E.F., Ginsberg M.H. Monoclonal Antibodies to Ligand-occupied Conformers of Integrin αIIbβ3 (glycoproteinIIb-IIIa) alter Receptor Affinity, Specifinity, and function. J. Biol. Chem. 1991; 266(26)17106–17111
   PubMed Web of Science ®Google Scholar
• Mcmihan R., Lopez-Dee J., Loftus J.C. Autoantibodies to alpha (IIb) beta (3) in Patients with Chronic Immune Thrombocytopenic Purpura bind Primarily to Epitopes on alpha (IIb). Blood 2001; 97(7)2171–2172
   Google Scholar
• Kosugi S., Tomiyama Y., Shiraga M. Platelet-associated Anti-glycoprotein (GP) IIb-IIIa Auto-antibodies in Chronic Immune Thyombocytopenic Purpura mainly Recognize Cation-dependent Conformations: Comparison with Epitopes of Serum Autoantibodies. Thromb. Haemost. 1996; 75(3)339–345
   Google Scholar
• Murray J.S. How the MHC Selects Th1/Th2 Immunity. Immunol. Today 1998; 19(1)157–163
   Google Scholar
• Ohashi P.S. T Cell Selection and Autoimmunity: Flexibility and Tuning. Curr. Opin. Immunol. 1996; 8(6)808–814
   Google Scholar
• Pardoll D.M. Inducing Autoimmune Disease to Treat Cancer. Proc. Natl. Acad. Sci. USA 1999; 96(10)5340–5342
   PubMed Web of Science ®Google Scholar
• Willem W.O., David S.L., Deboran R.S., Kari R.I., Christopher E.T., Chan C.-C., Mils W.C., Bernard M., Steven A.R., Nicholas P.R. Vaccination with a Recombinant Vaccinia Virus Encoding a “self” Antigen Induces Autoimmune Vitiligo and Tumor Cell Destruction in Mice: Requirement for CD4+ T Lymphocytes. Proc. Natl. Acad. Sci. USA 1999; 96(16)2982–2987
   Google Scholar
• Mosmann T.R., Sad S. The Expanding Universe of T-cell Subsets: Th1, Th2 and more. Immunol. Today 1996; 17(3)138–146
   PubMedGoogle Scholar
• Kumar V., Stellrecht K., Sercarz E. Inactivation of T cell Receptor Peptide-specific CD4 Regulatory T cells Induces Chronic Experimental Autoimmune Encephalomyelitis (EAE). J. Exp. Med. 1996; 184(5)1609–1617
   Google Scholar
• De Silva H.D., Van Driel I.R., La Gruta N., Toh B.H., Gleeson P.A. CD4+ T cells, but not CD8+ T cells, are Required for the Development of Experimental Autoimmune Gastritis. Immunology 1998; 93(3)405–408
   PubMed Web of Science ®Google Scholar
• Billaut M.O., Cocude C., Kolesnitchenko V., Truong M.J., Chan E.K., Hachula E., Tribonniere X., Capron A., Bahr G.M. SS-56, a Novel Cellular Target of Autoantibody Responses in Sjogren Syndrome and Systemic Lupus Erythematosus. J. Clin. Invest. 2001; 108(6)861–819
   Google Scholar